Income statement
EUR
Annual
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 57M | 48M | 43M | 37M |
| Gross Profit | 28M | 14M | 17M | 16M |
| Operating Income | -47M | -63M | -47M | -56M |
| EBITDA | -44M | -53M | -43M | -47M |
| Net Income | -65M | -71M | -63M | -64M |
| EPS (Diluted) | — | — | — | — |
Healthcare
Live Price
Offline$0.66
-85.33% today
1Y Change
—
Window
No data
Historical coverage is still loading
We are still backfilling 1Y daily history for this symbol. Some charts may stay empty until more data arrives.
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Biocartis Group N.V. (BIOGF) is a Healthcare stock with a market cap of $65.41M. The stock last traded around $0.66. Baseline metrics include revenue growth of +19.1%, EPS growth of +12.9%, a dividend yield of 0.0%. What stands out right now is revenue +19.1%, EPS +12.9%, free cash flow +32.6% with operating margin -81.8% and ROIC -50.7%. Valuation is more restrained than many high-expectation growth names at price/sales 0.5. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines BIOGF price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
BIOGF
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
BIOGF Max Drawdown
—
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for BIOGF and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$37.4M
-13.2% YoY
FY Net Income
-$64.1M
-1.8% YoY
Free Cash Flow
-$56.8M
-34.2% YoY
Revenue Growth
+19.1%
EPS Growth
+12.9%
Gross Margin
48.2%
Net Margin
-113.7%
Income statement
EUR
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Revenue | 57M | 48M | 43M | 37M |
| Gross Profit | 28M | 14M | 17M | 16M |
| Operating Income | -47M | -63M | -47M | -56M |
| EBITDA | -44M | -53M | -43M | -47M |
| Net Income | -65M | -71M | -63M | -64M |
| EPS (Diluted) | — | — | — | — |
Balance sheet
EUR
| Metric | 2022 | 2021 | 2020 | 2019 |
|---|---|---|---|---|
| Cash & Equivalents | 25M | 52M | 122M | 178M |
| Total Assets | 114M | 142M | 211M | 268M |
| Total Liabilities | 145M | 176M | 174M | 184M |
| Shareholder Equity | -30M | -34M | 37M | 84M |
| Total Debt | 122M | 154M | 151M | 167M |
| Net Debt | 97M | 102M | 28M | -11M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
54M
-38.2% YoY
Capital Expenditures
3M
+16.7% YoY
Free Cash Flow
57M
-34.2% YoY
Key ratios
Gross Margin
48.2%
Operating Margin
-81.8%
Net Margin
-113.7%
ROE
203.7%
Debt / Equity
-4.04x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.